We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation.
- Authors
Uchida, N; Gondo, H; Himeji, D; Kaji, Y; Sata, M; Niho, Y
- Abstract
Hepatitis B virus (HBV) can be a cause of fatal liver failure after chemotherapy for viral carrier patients and limits the indication of myeloablative therapy for them. We describe an HBsAg-positive leukemia patient who successfully underwent autologous PBSC transplant. After chemotherapeutic treatment his serum HBV DNA level rose in association with hepatitis. To prevent progression to fulminant hepatitis, we administered lamivudine, a viral reverse transcriptase inhibitor, during the transplantation procedure. The patient did not show any increase of HBV DNA or a worsening of his hepatitis. Thus, lamivudine may be a promising treatment for HBsAg-positive patients receiving myeloablative chemotherapy and autologous stem cell transplantation. Bone Marrow Transplantation (2000) 26, 1243–1245.
- Subjects
HEPATITIS B virus; LIVER failure; DRUG therapy; LEUKEMIA; HEPATITIS
- Publication
Bone Marrow Transplantation, 2000, Vol 26, Issue 11, p1243
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1702693